Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics (Nasdaq: CGEM) announced that the REZILIENT3 Phase 3 clinical trial evaluating zipalertinib combined ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE